Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma

Cell Cycle

Volumn 10, Issue 17, 2011, Pages 2994-3002

  He, Jing ^a   Gu, Lubing ^a   Zhang, Hailong ^a   Zhou, Muxiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell growth; MDM2; MYCN; Neuroblastoma; p53

Indexed keywords

PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROTEIN INTERACTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 80052399440     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.17.17118     Document Type: Article

References (25)

1. Bowen K.A., Chung DH. Recent advances in neuroblastoma. Curr Opin Pediatr 2009; 21:350-6; PMID:19381091; DOI:10.1097/MOP.0b013e32832b1240.
2. Mueller S., Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep 2009; 11:431-8; PMID:19840520; DOI:10.1007/s11912-009-0059-6.
3. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17:2264-2279; PMID:10561284.
4. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121-4; PMID:6719137; DOI:10.1126/science.6719137.
5. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6; PMID:4047115; DOI:10.1056/NEJM198510313131802.
6. Tonini G.P., Boni L., Pession A., Rogers D., Iolascon A., Basso G., et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience with 295 children. J Clin Oncol 1997; 15:85-93; PMID:8996128.
7. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-Cis-retinoic acid. N Engl J Med 1999; 341:1165-73; PMID:10519894; DOI:10.1056/NEJM199910143411601.
8. Carr-Wilkinson J., O'Toole K., Wood K.M., Challen C.C., Baker A.G., Board J.R., et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 2010; 16:1108-18; PMID:20145180; DOI:10.1158/1078-0432.CCR-09-1865.
9. Cattelani S., Defferrari R., Marsilio S., Bussolari R., Candini O., Corradini F., et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin Cancer Res 2008; 14:3248-53; PMID:18519749; DOI:10.1158/1078-0432.CCR-07-4725.
10. Corvi R., Savelyeva L., Breit S., Wenzel A., Handgretinger R., Barak J., et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995; 10:1081-1086; PMID:7700632.
11. Momand J., Zambetti G.P., Olson D., George D., Levine AJ. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45; PMID:1535557; DOI:10.1016/0092-8674(92) 90644-R.
12. Haupt Y., Maya R., Kazaz A., Oren M. MDM2 promotes the rapid degradation of p53. Nature 1997; 387:296-9; PMID:9153395; DOI:10.1038/387296a0.
13. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375:694-8; PMID:7791904; DOI:10.1038/375694a0.
14. Zhang Z., Wang H., Li M., Rayburn E.R., Agrawal S., Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24:7238-47; PMID:16170383; DOI:10.1038/sj.onc.1208814.
15. Elenbaas B., Dobbelstein M., Roth J., Shenk T., Levine A.J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996; 2:439-451; PMID:8827714.
16. Gu L., Zhu N., Zhang H., Durden D.L., Feng Y., Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009; 15:363-75; PMID:19411066; DOI:10.1016/j. ccr.2009.03.002.
17. Slack A., Chen Z., Tonelli R., Pule M., Hunt L., Pession A., et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. ProcNatlAcadSci USA 2005; 102:731-6; PMID:15644444; DOI:10.1073/pnas.0405495102.
18. Chen L., Iraci N., Gherardi S., Gamble L.D., Wood K.M., Perini G., et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2010; 70:1377-88; PMID:20145147; DOI:10.1158/0008-5472.CAN-09-2598.
19. Gu L., Zhang H., He J., Li J., Zhou M. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene In press; PMID:21822304.
20. Lutz W., Stöhr M., Schürmann J., Wenzel A., Löhr A., Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13:803-812; PMID:8761302.
21. Fulda S., Lutz W., Schwab M., Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999; 18:1479-86; PMID:10050884; DOI:10.1038/sj.onc.1202435.
22. Cohn S.L., London W.B., Huang D., Katzenstein H.M., Salwen H.R., Reinhart T., et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000; 18:3604-3613; PMID:11054433.
23. Shohet J.M., Hicks M.J., Plon S.E., Burlingame S.M., Stuart S., Chen S.Y., et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002; 62:1123-1128; PMID:11861392.
24. Takisawa H., Mimura S., Kubota Y. Eukaryotic DNA replication: from pre-replication complex to initiation complex. Curr Opin Cell Biol 2000; 12:690-6; PMID:11063933; DOI:10.1016/S0955- 0674(00)00153-8.
25. Ochiai H., Takenobu H., Nakagawa A., Yamaguchi Y., Kimura M., Ohira M., et al. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 2010; 29:2681-90; PMID:20190806; DOI:10.1038/onc.2010.22.